The year 2023 began with a promising after-effect of the extremely successful 2022 financial year for Budenheim. However, in the further course of the year, the lasting risks in the field of the gas supply, rising raw material prices and fluctuating demand had a negative impact on the development of the company’s business. For this reason, the 2022 record revenue was not repeated – as had been expected. Sales revenue declined by 15.6% to EUR 439 million and was, hence, significantly below the forecast. Of this figure, 30% was attributable to the Material Science division and 70% to the Life Science division.
In 2023, Budenheim successfully concluded two of its biggest investments in new capacities. Thus, the ammonium polyphosphate (APP) production line at the La Zaida site in Spain was commissioned in September. Moreover, commissioning of the “House of Nutrition” in Budenheim is also on schedule. Mechanical completion of the combined production line for calcium and magnesium phosphates was successfully completed by the end of the year.
Budenheim is a medium-sized company with an international presence that offers solutions for ambitious endeavours in the realm of specialty chemicals. Its product and service portfolio is divided into two operating divisions, Life Science and Material Science. As a chemical specialist, in close cooperation with its customers, the company actively develops solutions in the fields of nutrition, health, safety and resource preservation.